• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

solid tumor

Merck  Co headquarters
Biotech

Merck’s TROP2 ADC extends survival in pivotal cancer trial

Sac-TMT improved overall survival in a phase 3 cancer trial, delivering a second pivotal global win for the TROP2-directed antibody-drug conjugate.
Nick Paul Taylor Nov 20, 2026 11:20am
cancer target detection radiopharma radio

Onchilles harnesses new cancer-killing pathway to tackle tumors

Nov 9, 2026 1:30pm
milestones

Faeth’s data power oral combo forward in cancer targeted by ADCs

Nov 9, 2026 7:00am
Merck ESMO 2026

Merck ends Sutro-partnered IL-2 drug in ‘routine prioritization’

Nov 6, 2026 4:20am
AbbVie booth at AACR 2026

AbbVie drops ph. 2 solid tumor drug over ‘limited benefit’

Nov 3, 2026 8:38am
Pfizer

Pfizer trims obesity pipeline, axes phase 2 lung disease asset

Nov 3, 2026 8:02am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings